HOUSTON, Nov. 4, 2025 /PRNewswire/ -- Delphi Diagnostics announces the upcoming presentation of four scientific abstracts, including one platform presentation highlighting new clinical data supporting ...
GS3-05: Evaluation of the Sensitivity to Endocrine Therapy (SETER/PR) assay to predict benefit from extended endocrine therapy in the NRG/NSABP B-42 trial Author: Eleftherios P Mamounas, AdventHealth ...
Setting 13 class A tertiary hospitals and 2 universities. Participants Nine experts were selected for expert interview: (1) bachelor’s degree or higher; (2) ≥10 years’ experience in burn care, nursing ...
In an era marked by tight hospital margins and rising antimicrobial resistance, diagnostics are emerging not just as tools for detection, but as strategic assets that can influence clinical outcomes ...
Office Licensing Diagnostic Tool is a command-line utility that allows system administrators to gather information about users’ problems with Office activation. After collecting all the log files, you ...
Delphi Diagnostics Inc. is a Texas-based company focused on advancing clinically valid tests for the prognosis and prediction of breast cancer treatment. Delphi Diagnostics, Inc. holds an exclusive ...
The latest software release extends the diagnostic tools’ capabilities with 2025 model year updates for 14 OEMs as well as ...
Background Renal denervation (RDN) has emerged as a guideline-recommended therapeutic option in hypertension management with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback